Drug Type Antibody drug conjugate (ADC) |
Synonyms Trastuzumab-T1000-exatecan, MTX 1000, MTX1000 |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC24H22FN3O4 |
InChIKeyZVYVPGLRVWUPMP-FYSMJZIKSA-N |
CAS Registry171335-80-1 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | China | 03 Apr 2023 | |
| Lung Cancer | Preclinical | China | 03 Apr 2023 |






